Carcinoma of the Cervix - Exam-Oriented Description

---

1. EPIDEMIOLOGY

• Fourth most common cancer in women worldwide; most common gynecologic cancer in developing countries.
• In the United States: ~12,578 new cases/year; ~4,115 deaths/year (CDC 2014 data). Lifetime probability: 1:128.
• Mean age at diagnosis: 47 years; bimodal distribution with peaks at 35-39 years and 60-64 years.
• 30% of cases in the US occur in women who have never had a Pap smear; in developing countries, this approaches 60%.
• Incidence is decreasing worldwide due to screening programs and vaccination.
• (Berek & Novak's Gynecology, p. 2217)

---

2. ETIOLOGY AND RISK FACTORS

Primary Cause

• HPV infection is detected in up to 99% of squamous cervical carcinomas - it is the causal agent.

• 100 HPV types; >30 affect the lower genital tract; 15 are high-risk.

• HPV 16 and 18 account for up to 70% of cervical carcinomas.
• Mechanism: HPV E6 protein inactivates p53 (prevents apoptosis/cell cycle arrest); HPV E7 protein inactivates Rb (disrupts E2F, causing unregulated proliferation).

Other Risk Factors

• Early age at first intercourse (<16 years)
• Multiple sexual partners
• Cigarette smoking
• High parity
• Low socioeconomic status
• Chronic immunosuppression (HIV - cervical cancer is an AIDS-defining illness)
• Long-term oral contraceptive use (>5 years: RR 1.6; >10 years: RR 2.2)
• Herpes simplex virus and Chlamydia trachomatis - cofactors
• (Berek & Novak's Gynecology, p. 2217-2218)

---

3. PATHOLOGY (HISTOLOGIC TYPES)

Squamous Cell Carcinoma (~70-75%)

• Most common type. Originates at the squamocolumnar junction (transformation zone).
• Precursor: Cervical Intraepithelial Neoplasia (CIN) - CIN 1 → CIN 2 → CIN 3 → Invasive.
• Subtypes: Keratinizing, non-keratinizing, basaloid, warty, papillary.

Adenocarcinoma (~20-25%)

• Relative and absolute incidence is increasing.
• Arises from endocervical glandular epithelium.
• Types: Mucinous (most common), endometrioid, clear cell, minimal deviation (adenoma malignum - associated with Peutz-Jeghers syndrome).
• Precursor: Adenocarcinoma in situ (AIS).
• Less easily detected by cervical cytology screening.

Adenosquamous Carcinoma

• Mixed glandular and squamous elements; more aggressive behavior.

Other Rare Types

• Neuroendocrine carcinoma (small cell - most aggressive, worst prognosis)
• Sarcoma (rare)
• Malignant melanoma (rare)

---

4. PATTERNS OF SPREAD

1. Direct extension - to vagina, parametrium, bladder (anterior), rectum (posterior), uterine corpus
2. Lymphatic spread - to paracervical → obturator → external iliac → common iliac → para-aortic nodes; also to presacral nodes
3. Hematogenous spread - to lungs, liver, bone (late, uncommon)

• Stage III: lower 1/3 vagina involvement, pelvic sidewall extension, hydronephrosis, or lymph node metastasis
• Ovarian metastasis: only 0.9% in early-stage - ovarian conservation is generally safe in squamous histology

---

5. CLINICAL FEATURES

Symptoms

• Early disease: Often asymptomatic; detected on routine Pap smear
• Classic symptom: Post-coital bleeding (most common presenting symptom)
• Intermenstrual bleeding, postmenopausal bleeding
• Vaginal discharge (watery, mucoid, or blood-stained; can be malodorous with necrosis)
• Pelvic pain (late/advanced disease)
• Advanced disease: Hematuria, rectal bleeding (bladder/bowel involvement), lower limb edema (lymphatic/venous obstruction), uremia (ureteral obstruction)

Signs

• Early: Visible ulceration or exophytic lesion on cervix; may be normal-looking with microinvasion
• Advanced: Friable, bleeding, barrel-shaped cervix; parametrial induration
• Ureteral obstruction - indicates stage III or worse
• Colposcopic/visual findings: Atypical vessels, mosaic pattern, punctuation, acetowhite areas

---

6. DIAGNOSIS AND EVALUATION

Screening

• Pap smear (cervical cytology) - foundation of screening
• HPV co-testing now recommended alongside cytology
• Bethesda system for reporting Pap results (NILM, ASC-US, LSIL, HSIL, AGC, carcinoma)

Diagnostic Workup

• Colposcopy with directed biopsy - gold standard for visualization
• Cervical punch biopsy - confirms invasive disease
• Cone biopsy (LEEP/cold knife) - for microinvasive disease diagnosis and treatment
• Endocervical curettage (ECC) - to evaluate endocervical canal

Imaging (for staging/treatment planning)

• MRI pelvis - best for assessing parametrial invasion, tumor size, and depth of stromal invasion (most accurate)
• CT chest/abdomen/pelvis - lymph node assessment
• PET/CT - most sensitive for lymph node metastases and distant spread (incorporated in 2018 FIGO staging)
• Cystoscopy and proctoscopy - clinically indicated to detect bladder/rectal invasion (for FIGO purposes)

---

7. STAGING - FIGO 2018 (Key Update)

• Horizontal spread no longer considered in Stage IA - only depth of invasion used
• Stage IB now divided into 3 substages (IB1, IB2, IB3) reflecting fertility-sparing advances
• Stage IIIC added to capture lymph node metastasis (noted by "r" for imaging or "p" for pathologic: e.g., IIIC1r vs IIIC1p)
• When staging is in doubt, assign the lower (earlier) stage
• Once stage is assigned and treatment started, stage cannot be changed
• (Berek & Novak's Gynecology, p. 2223-2224)

---

8. TREATMENT BY STAGE

Overview Table (Berek & Novak's, Table 38-4)

Surgery

• Type I (Extrafascial) hysterectomy - for IA1 without LVSI
• Type II (Modified radical) hysterectomy - for IA2, smaller IB1; preserves more bladder innervation
• Type III (Radical/Wertheim's) hysterectomy - for IB1, IB2, IIA; removes parametria and upper vaginal cuff with pelvic LND
• Radical trachelectomy - fertility-sparing; for IB1 (<2 cm); combined with pelvic LND/SLN biopsy
• Pelvic exenteration - for central recurrence after radiotherapy; three types: anterior, posterior, total

• Ovarian conservation possible
• Avoids radiation-induced vaginal fibrosis and atrophy
• Surgical complications (fistulae, bladder injury) are usually repairable
• Operative mortality <1%; urinary fistula rate <2%
• Radical hysterectomy not recommended for lesions >4 cm (will require post-op radiation)
• (Berek & Novak's Gynecology, p. 2237)

Sentinel Lymph Node (SLN) Biopsy

• Increasingly used to replace full pelvic lymphadenectomy in early-stage disease
• Reduces morbidity (lymphedema, lymphocyst formation)

Radiation Therapy

• External beam radiation therapy (EBRT) + intracavitary brachytherapy = standard for IIB-IVA
• Intensity-Modulated Radiation Therapy (IMRT) - reduces dose to bladder/bowel
• Image-guided adaptive brachytherapy (IGABT) - modern standard for intracavitary boost
• Complications: Proctitis, cystitis, vaginal stenosis, fistulae (bladder, rectovaginal)

Concurrent Chemoradiation

• Cisplatin (40 mg/m², weekly) + pelvic EBRT + brachytherapy = standard for IB3 and above
• Cisplatin acts as a radiation sensitizer
• Five pivotal RCTs (1999 GOG) established cisplatin-based chemoradiation as superior to radiation alone
• (Berek & Novak's Gynecology, p. 2247)

Prognostic Variables for Early-Stage Cervical Cancer (IA2-IIA) After Radical Hysterectomy

• Positive lymph nodes (pelvic or para-aortic)
• Positive surgical margins
• Parametrial involvement

• Large tumor size
• Deep stromal invasion
• Lympho-vascular space invasion (LVSI)

---

9. TREATMENT OF ADVANCED/RECURRENT DISEASE

Systemic Chemotherapy

• For Stage IVB, persistent, recurrent, or metastatic disease
• First-line doublet: Cisplatin + paclitaxel (preferred) or carboplatin + paclitaxel
• Bevacizumab (VEGF inhibitor) added to chemotherapy (GOG 240 trial) - improved OS from 13.3 to 17.0 months

Immunotherapy - KEY 2021 UPDATE (KEYNOTE-826)

• Pembrolizumab (anti-PD-1) + chemotherapy ± bevacizumab - FDA approved October 13, 2021 for first-line treatment of persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS ≥ 1
• First anti-PD-1 combination approved for first-line cervical cancer
• KEYNOTE-826 results: In PD-L1 CPS ≥1 patients, median OS: 28.6 months (pembrolizumab) vs. 16.5 months (placebo); HR = 0.64
• Updated 2023 ASCO data confirmed benefit regardless of PD-L1 status
• Pembrolizumab monotherapy also FDA-approved as single agent for recurrent/metastatic cervical cancer with PD-L1 CPS ≥1 after prior chemotherapy

Pelvic Exenteration

• Only potentially curative option for isolated central pelvic recurrence after prior radiation
• 5-year survival ~50% in highly selected patients
• Absolute contraindications: Metastatic disease, bilateral pelvic sidewall involvement ("frozen pelvis"), poor performance status
• (Berek & Novak's Gynecology, p. 2275)

---

10. SPECIAL CONSIDERATIONS

Cervical Cancer in Pregnancy

• Diagnosed by Pap smear/colposcopy during antenatal care
• If <Stage IB2: Delay treatment until fetal maturity possible (under close surveillance)
• Classical cesarean section (to avoid cervical incision) + definitive treatment postpartum
• Stage IB3 and above: Treatment cannot safely be delayed

Barrel-Shaped Cervix

• Tumor >6 cm in diameter; confined to cervix; centrally located
• Poor access for brachytherapy; higher recurrence rate
• Extrafascial hysterectomy after chemoradiation may be used (though survival benefit debated)

Cancer After Simple Hysterectomy

• Microinvasive (low risk) - no further treatment needed
• Invasive - radiotherapy or radical reoperation (parametrectomy + vaginal cuff excision + pelvic LND)
• Post-op radiotherapy outcome: 95-100% 5-year survival for microscopic disease; 20-47% for gross residual

Ureteral Obstruction

• Indicates at least Stage IIIB
• Nephrostomy tube placement to preserve renal function before treatment

Acute Hemorrhage

• Vaginal packing with Monsel's solution + emergent radiation
• Vascular embolization for severe cases

---

11. PROGNOSIS / 5-YEAR SURVIVAL BY STAGE

---

12. PREVENTION

HPV Vaccination

• Gardasil (quadrivalent) - HPV 6, 11, 16, 18; efficacy 97-100% for CIN2/3 in HPV-naive women; 44% in those previously infected
• Cervarix (bivalent) - HPV 16, 18
• Gardasil-9 (9-valent) - adds HPV 31, 33, 45, 52, 58; now preferred; non-inferior immunogenicity compared to quadrivalent
• Recommended for females and males aged 9-26; can be given up to age 45 (shared decision-making)
• Vaccinating before sexual debut provides maximum benefit
• (Berek & Novak's Gynecology, p. 2718-2719)

Screening (Current Recommendations)

• Age 21-29: Pap smear alone every 3 years
• Age 30-65: Pap smear + HPV co-testing every 5 years (preferred) or Pap alone every 3 years
• >65 years: Can stop screening if adequate prior negative testing
• After hysterectomy (no cervix, no history of CIN2+): No further screening needed

---

13. RECENT UPDATES (2023-2026)

---

Key Exam Points at a Glance

• HPV 16/18 → 70% of cervical carcinomas; E6 → degrades p53; E7 → inhibits Rb
• Most common histology: Squamous cell carcinoma; adenocarcinoma incidence is increasing
• Staging is clinical + imaging/pathology (FIGO 2018); once started, stage cannot be changed
• LVSI + depth + size = determine adjuvant therapy after radical hysterectomy
• Microinvasion <3 mm without LVSI: cone biopsy is adequate if margins clear
• Concurrent cisplatin-based chemoradiation = standard for IIB and above
• Pembrolizumab (PD-L1 CPS ≥1) + chemo ± bevacizumab = first-line standard for metastatic/recurrent disease (KEYNOTE-826)
• Pelvic exenteration = curative option for isolated central recurrence post-radiation
• LACC trial: Open radical hysterectomy preferred over minimally invasive for early cervical cancer

Sources: Berek & Novak's Gynecology (16th ed.), pp. 2217-2280; Robbins Pathologic Basis of Disease; KEYNOTE-826 [PMID: various]; ESGO-ESTRO-ESP 2023 guidelines; PMID 39216500 (Lancet Oncol 2024 fertility-sparing guidelines)

Note: Williams Gynecology was not available in the textbook library; the above is drawn from Berek & Novak's Gynecology (the most comprehensive gynecologic oncology reference in the library) and current evidence.Note on sources: Williams Gynecology (Shaw's) was not present in the textbook library - the above is drawn from Berek & Novak's Gynecology (the definitive gynecologic oncology textbook in the library), verified against Robbins Pathology and supplemented with current guidelines and trials.

---

---

CARCINOMA CERVIX - Complete Exam Guide

---

1. EPIDEMIOLOGY

• 4th most common cancer in women worldwide; leading gynecologic cancer in developing countries.
• US incidence: ~12,578 new cases/year; ~4,115 deaths/year.
• Lifetime risk: 1 in 128 women.
• Mean age: 47 years; bimodal peaks at 35-39 years and 60-64 years.
• 30% of US cases occur in women who never had a Pap smear; in developing countries, this approaches 60%.
• Considered a preventable disease - long preinvasive state, effective screening, and treatable precursors.

---

2. ETIOLOGY AND PATHOGENESIS

Causal Agent: Human Papillomavirus (HPV)

• Detected in up to 99% of squamous cervical carcinomas.

• 100 HPV types; 15 are high-risk.

• HPV 16 and 18 found in up to 70% of cervical carcinomas.
• Mechanism of carcinogenesis:
  • E6 protein binds and degrades p53 → prevents apoptosis and cell cycle arrest at G1 checkpoint
  • E7 protein binds and inactivates Rb (retinoblastoma protein) → disrupts E2F transcription factor → unregulated cellular proliferation
  • Both steps are essential for malignant transformation.
• HPV causes both squamous cell carcinoma and adenocarcinoma (possibly via different carcinogenic pathways).

Cofactors

• Herpes simplex virus type 2 (HSV-2)
• Chlamydia trachomatis
• HIV (immune suppression) - cervical cancer is an AIDS-defining illness

Risk Factors

---

3. PATHOLOGY

A. Squamous Cell Carcinoma (~70-75%)

• Most common type. Arises from the transformation zone (squamocolumnar junction).
• Sequence: Normal epithelium → HPV infection → CIN 1 → CIN 2 → CIN 3/CIS → Invasive carcinoma.
• Subtypes: Large-cell keratinizing, large-cell non-keratinizing (most common), small cell, basaloid, papillary, warty.
• Verrucous carcinoma - rare, locally invasive, almost never metastasizes.

B. Adenocarcinoma (~20-25%)

• Arises from endocervical columnar epithelium.
• Incidence is increasing (both relative and absolute).
• Subtypes: Mucinous (most common), endometrioid, clear cell, serous.
• Minimal deviation adenocarcinoma (adenoma malignum) - associated with Peutz-Jeghers syndrome; deceptively bland histology.
• Less effectively detected by cytologic screening.
• Precursor: Adenocarcinoma in situ (AIS).

C. Adenosquamous Carcinoma

• Mixed glandular and squamous elements. More aggressive behavior.

D. Other Rare Types

• Neuroendocrine/small cell carcinoma - most aggressive; worst prognosis; treated like small cell lung cancer (cisplatin + etoposide)
• Glassy cell carcinoma - variant of poorly differentiated adenosquamous
• Lymphoepithelioma-like carcinoma - better prognosis
• Sarcoma, melanoma - rare

---

4. PATTERNS OF SPREAD

1. Direct extension:
   • Downward to vagina
   • Lateral to parametrium → pelvic sidewall
   • Anteriorly to bladder (vesicovaginal fistula)
   • Posteriorly to rectum (rectovaginal fistula)
   • Superiorly to uterine corpus
2. Lymphatic spread (most important clinical route):
   • Paracervical → Obturator → External iliac → Internal iliac → Common iliac → Para-aortic nodes
   • Also to presacral nodes
3. Hematogenous spread (late):
   • Lungs, liver, bone - uncommon in early disease

---

5. CLINICAL FEATURES

Symptoms

• Early: Often asymptomatic; abnormal Pap smear only finding
• Classic presenting symptom: Post-coital bleeding
• Intermenstrual or postmenopausal bleeding
• Vaginal discharge - watery, serous, or blood-stained; malodorous with necrosis
• Pelvic/back pain (advanced disease - suggests pelvic sidewall or nerve involvement)
• Advanced: Hematuria, rectal bleeding (vesical/rectal invasion), lower limb edema (lymphatic obstruction), uremia (bilateral ureteral obstruction)

Signs

• Exophytic, ulcerating, or endophytic (barrel-shaped) cervical lesion
• Friable cervix that bleeds on touch
• Parametrial thickening on rectal examination
• "Frozen pelvis" (bilateral parametrial involvement to pelvic sidewall) - advanced disease

---

6. DIAGNOSIS

---

7. FIGO STAGING 2018 (Current)

• Imaging (CT, MRI, PET) and pathologic findings now incorporated into staging.
• Horizontal spread no longer part of Stage IA - only depth of stromal invasion.
• Stage IB now has 3 substages (IB1, IB2, IB3).
• Stage IIIC added for pelvic (IIIC1) and para-aortic (IIIC2) lymph node metastasis; further designated by "r" (radiologic) or "p" (pathologic) - e.g., IIIC1r or IIIC1p.
• When doubt exists about stage: assign the earlier stage.
• Stage once assigned must not be changed after treatment begins.

---

8. TREATMENT SUMMARY BY STAGE

Microinvasive Disease (Stage IA)

• Desire fertility: Cone biopsy (margins and ECC must be negative)
• No fertility desire: Extrafascial (Type I) hysterectomy
• Note: <1% risk of pelvic lymph node metastasis → lymphadenectomy NOT needed

• Modified radical trachelectomy (fertility) OR modified radical hysterectomy + pelvic LND/SLN

Early Invasive Disease (IB1, IB2, IIA1)

• Radical trachelectomy + pelvic LND (if fertility desired; lesion <2 cm)
• OR Type III (Radical Wertheim's) hysterectomy + pelvic LND

• Type III radical hysterectomy + pelvic LND (for IB2, some centers)
• Concurrent cisplatin-based chemoradiation (especially IB3, IIA2 ≥4 cm)
• Not advisable to do radical hysterectomy for >4 cm lesions (high rate of requiring post-op RT)

Locally Advanced Disease (IIB-IVA)

• Standard: Concurrent cisplatin-based chemoradiation (cisplatin 40 mg/m² weekly + EBRT + brachytherapy)
• Cisplatin alone is the preferred radiosensitizer

Stage IVB / Metastatic / Recurrent

• Cisplatin + paclitaxel
• Carboplatin + paclitaxel
• Bevacizumab (VEGF inhibitor) added to doublet - improved median OS (17 vs 13.3 months; GOG 240)

• Pembrolizumab + chemotherapy ± bevacizumab - FDA approved October 2021 (KEYNOTE-826) for first-line treatment of persistent/recurrent/metastatic cervical cancer with PD-L1 CPS ≥ 1
• Median OS: 28.6 months (pembrolizumab) vs. 16.5 months (placebo)
• Updated final data (ASCO 2023): benefit persists and is seen regardless of PD-L1 status
• Pembrolizumab monotherapy - approved for second-line (post-chemotherapy) PD-L1 CPS ≥1

---

9. ADJUVANT THERAPY AFTER RADICAL HYSTERECTOMY

High-risk features (→ Adjuvant cisplatin-based chemoradiation):

• Positive pelvic lymph nodes
• Positive surgical margins
• Parametrial involvement

Intermediate-risk features (Sedlis criteria - → Adjuvant pelvic radiation):

• Combination of: large tumor size + deep stromal invasion + LVSI

---

10. RECURRENT DISEASE

• 35% of patients with invasive cervical cancer will have recurrent/persistent disease.
• Central pelvic recurrence: potentially curable with pelvic exenteration.
• Lateral pelvic/distant recurrence: palliative treatment only.

Pelvic Exenteration Types:

1. Anterior exenteration - bladder + vagina + uterus + cervix
2. Posterior exenteration - rectum + vagina + uterus + cervix
3. Total exenteration - bladder + rectum + vagina + uterus + cervix (± infralevator/supralevator)

---

11. PREVENTION

HPV Vaccination

• Gardasil-9 (9-valent) - now preferred; covers HPV 6, 11, 16, 18, 31, 33, 45, 52, 58
• 97-100% efficacy for CIN2/3 in HPV-naive recipients
• Recommended: Ages 9-12 (routine), 13-26 (catch-up), up to age 45 (shared decision-making)
• Given to both males and females

Cervical Cancer Screening

---

12. PROGNOSIS

---

13. RECENT UPDATES AND GUIDELINES (2023-2026)

---

• "HPV causes Cervical cancer - E6 kills p53, E7 kills Rb"
• IIB and above = Chemoradiation (not surgery as primary)
• IIIC = Nodes (new in 2018 FIGO)
• Pembrolizumab = first-line for metastatic if PD-L1 CPS ≥1 (KEYNOTE-826)
• LACC trial = Open > Laparoscopic for radical hysterectomy